Salivary bacterial signatures in depression-obesity comorbidity are associated with neurotransmitters and neuroactive dipeptides

Suzi Hong (✉ s1hong@health.ucsd.edu)

University of California San Diego

Gajender Aleti

University of California San Diego

Jordan N. Kohn

University of California San Diego

Emily A. Troyer

University of California San Diego

Kelly Weldon

University of California San Diego

Shi Huang

University of California San Diego

Anupriya Tripathi

University of California San Diego

Pieter C. Dorrestein

University of California San Diego

Austin D. Swafford

University of California San Diego

Rob Knight

University of California San Diego

Research article

Keywords: depressive symptomatology, obesity, depressive symptomatology-obesity comorbidity, symptomatology independently

Posted Date: August 23rd, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-829379/v1>

License: This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

1 **Title page**

2 **Salivary bacterial signatures in depression-obesity comorbidity are associated with**
3 **neurotransmitters and neuroactive dipeptides**

4 Gajender Aleti¹ galeti@health.ucsd.edu, Jordan N. Kohn¹ jokohn@health.ucsd.edu, Emily A.
5 Troyer¹ etroyer@health.ucsd.edu, Kelly Weldon^{3,6} kweldon@eng.ucsd.edu, Shi Huang^{2,3}
6 shh047@health.ucsd.edu, Anupriya Tripathi^{2,6} anupriya.tripathi92@gmail.com, Pieter C.
7 Dorrestein^{2,3,6,7} pdorrestein@health.ucsd.edu, Austin D. Swafford³ adswafford@eng.ucsd.edu,
8 Rob Knight^{2,3,4,5} robknight@eng.ucsd.edu, Suzi Hong^{*1,8} slhong@health.ucsd.edu

9 **Affiliations**

10 ¹Department of Psychiatry, University of California San Diego, La Jolla, CA 92093, United
11 States of America.

12 ²Department of Pediatrics, University of California San Diego, La Jolla, CA 92093, United
13 States of America.

14 ³Center for Microbiome Innovation, University of California San Diego, La Jolla, CA 92093,
15 United States of America.

16 ⁴Department of Computer Science and Engineering, University of California San Diego, La
17 Jolla, CA 92093, United States of America.

18 ⁵Department of Bioengineering, University of California San Diego, La Jolla, CA 92093, United
19 States of America.

⁶Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, CA 92093, United States of America.

⁷Collaborative Mass Spectrometry Innovation Center, University of California San Diego, La Jolla, CA 92093, United States of America.

⁸Herbert Wertheim School of Public Health and Longevity Science, University of California San Diego, La Jolla, CA 92093, United States of America.

*Corresponding author: Suzi Hong, PhD; s1hong@health.ucsd.edu

Abstract

Background

Depression and obesity, both of which are highly prevalent and inflammation underlies, often co-occur. Microbiome perturbations are implicated in obesity-inflammation-depression interrelationships, but how microbiome alterations contribute to underlying pathologic processes remains unclear. Metabolomic investigations to uncover microbial neuroactive metabolites may offer mechanistic insights into host-microbe interactions.

Methods

Using 16S sequencing and untargeted mass spectrometry of saliva, and blood monocyte inflammation regulation assays, we determined key microbes, metabolites and host inflammation in association with depressive symptomatology, obesity, and depressive symptomatology-obesity comorbidity.

Results

Gram-negative bacteria with inflammation potential were enriched relative to Gram-positive bacteria in comorbid obesity-depression, supporting the inflammation-oral microbiome link in obesity-depression interrelationships. Oral microbiome was highly predictive of depressive symptomatology-obesity co-occurrences than obesity and depressive symptomatology independently, suggesting specific microbial signatures associated with obesity-depression co-occurrences. Mass spectrometry analysis revealed significant changes in levels of signaling molecules of microbiota, microbial or dietary derived signaling peptides and aromatic amino acids among host phenotypes. Furthermore, integration of the microbiome and metabolomics data revealed that key oral microbes, many previously shown to have neuroactive potential, co-occurred with potential neuropeptides and biosynthetic precursors of the neurotransmitters dopamine, epinephrine and serotonin.

Conclusions

Together, our findings offer novel insights into oral microbial-brain connection and potential neuroactive metabolites involved.

54 **Background**

55 Depression and obesity are common, debilitating, and frequently co-occurring chronic conditions
56 with increasing incidences globally [1]. Nearly 39% of the adult population are overweight and
57 13% are obese worldwide (WHO, 2016), while 5% of the world population are affected by mood
58 disorders (WHO, 2017) [2,3]. The relationship between obesity and depression is often
59 bidirectional [4], as prevalence of depression among individuals with obesity is significantly
60 higher than that in the general population [5,6]. Conversely, individuals with depression are more
61 likely to develop obesity compared to non-depressed individuals [7]. Despite the advent of
62 antidepressant drugs and their long-term usage in clinical treatment, the majority of patients with
63 depression are treatment-refractory, and obesity may further reduce the efficacy of
64 antidepressants [8]. Furthermore, comorbid depression and obesity are strongly associated with
65 several diseases such as type 2 diabetes mellitus, cardiovascular diseases, chronic kidney disease
66 and cancer, reducing both longevity and quality of life [2,9]. Therefore, obesity and depression,
67 and their co-occurrence, pose a major public health concern worldwide.

68 Inflammatory dysregulation is a common pathogenic mechanism underlying the co-
69 occurrence of depression and obesity, as both are associated with chronic low-grade
70 inflammation [10,11]. Individuals with obesity and depression evidence increased concentrations
71 of peripheral and central inflammatory cytokines and acute phase reactants, such as interleukin
72 (IL)-6, tumor necrosis factor alpha (TNF- α), and C-reactive protein (CRP) [11,12]. In obesity,
73 macrophages accumulate in adipose tissue leading to local and systemic inflammation [13,14],
74 which can contribute to depressive symptoms via multiple mechanisms, such as by decreasing
75 neurotransmitter availability, and by potentiating neuroinflammatory processes such as

76 microglial activation and peripheral monocyte trafficking to the central nervous system (CNS)
77 [10,15,16]. It should be noted, however, that inflammation has been shown to underlie only a
78 subset of depression cases [17], hence the conceptualization of a theoretical immuno-metabolic
79 *subtype* of major depressive disorder [18]. Nonetheless, inflammatory dysregulation remains a
80 central mechanism underlying the co-occurrence of depression and obesity, and this is likely
81 relevant to sub-clinical depressive symptomatology. To this end, our previous work has
82 demonstrated that even in individuals without clinical diagnosis of depression, higher depressive
83 symptom scores, obesity, and downregulated glucocorticoid and adrenergic receptor-mediated
84 cellular inflammatory control are interrelated [19–21].

85 Although psychological stress, host genetics and environmental factors have been shown
86 to contribute to obesity and depression, recently, the human microbiome (i.e., collection of
87 diverse microorganisms and their genetic material) and metabolome (i.e., a large collection of
88 structurally diverse metabolites) have been implicated in processes of energy homeostasis, mood
89 and behavior, and immune regulation, and may therefore offer a novel mechanism underlying the
90 co-occurrence of depression and obesity [2]. Animal studies of obesity have shown that depletion
91 of members of *Bifidobacterium*, *Lactobacillus*, and *Akkermansia* are associated with weight gain,
92 increased inflammation, increased depressive behavior and changes in neural circuitry [22,23].
93 Animal studies have also shown that increased permeability in the intestinal barrier and the
94 blood-brain barrier (BBB) are associated with increased plasma lipopolysaccharide (LPS) levels
95 [22–24] and neuroinflammation [23]. Altogether, these studies suggest that increased intestinal
96 barrier permeability and subsequent translocation of gut bacterial endotoxin, particularly LPS
97 from Gram-negative bacterial cell walls, into systemic circulation, is a source of chronic low-

98 grade inflammation and metabolic endotoxemia, which can potentiate neuroinflammatory
99 processes, and therefore serve as a potential mechanism underlying the occurrence of depressive
100 symptoms in the context of obesity. However, this remains to be established in humans.

101 It is to be noted that human microbiome studies in depression and obesity, and indeed in
102 health and disease, have focused largely on the ecosystem of the distal gut, while few studies
103 have examined the microbial ecology of the oral cavity outside of oral-related conditions such as
104 dental caries (i.e., tooth decay) and periodontitis (i.e., severe gum inflammation). The oral cavity,
105 an entry portal to both the digestive and respiratory tracts, contains the most diverse microbial
106 community after the gut, harboring more than 700 unique bacterial species with at least 150
107 specialized bacterial species per mouth [25,26]. More than 60% of the microbial species found in
108 the oral cavity have been shown to be potentially transmitted to the gut, suggesting that oral
109 cavity is a reservoir for gut microbial strains in shaping the gut microbiome in health and disease
110 [27]. Dysregulation of the unique microbe-microbe and microbe-host interactions in the oral
111 ecosystem has been associated with systemic inflammatory diseases such as inflammatory bowel
112 syndrome [28,29] beyond an array of oral diseases. In addition, oral microbiota have also been
113 associated with several neurological diseases, such as Alzheimer's disease (AD) [30], multiple
114 sclerosis [31] and Parkinson's disease [32]. Previously, our group found that salivary microbial
115 diversity and diurnal variability were associated with both peripheral proinflammatory cytokine
116 levels and psychological distress in this cohort on which this study is based [33]. The intimate
117 link between the oral microbiota and systemic human diseases, as evidenced by aforementioned
118 studies suggests that the oral cavity is likely a promising site for gaining insight into the
119 pathophysiology of depression-obesity comorbidity. Moreover, the oral cavity is easily

accessible via non-invasive as well as ‘on-demand’ collection of saliva samples for multi-omics applications.

While mechanisms linking the oral microbiota to the brain (i.e. “oral-brain axis”) remain largely unknown [34,35], recent studies have speculated several transmission routes of how oral bacteria may reach the brain and influence neuro-immune activity and inflammation [36]. For instance, routine dental procedures such as flossing, brushing and cleaning may cause oral bacteria to enter the blood circulation and cause bacteremia [37], and some of these microbes may traverse the BBB. Alteration in the permeability of the BBB may also expose the brain to bacterial metabolites triggering an inflammatory response, which in turn alters functioning of the CNS. For example, *Porphyromonas gingivalis*, a resident oral bacterium and a keystone pathogen in periodontitis has been found in the brain of AD patients [30] as well as neurotoxic proteases i.e., gingipains produced by *P. gingivalis* [30].

A recent study has shown that human gut bacteria encode at least 56 gut-brain metabolic pathways, which encompass both known and novel microbial pathways for synthesis and degradation of a number of neurotransmitters that have potential to cross the intestinal barrier and BBB [35]. A subset of these gut-brain pathway effectors, for instance dopamine, glutamate, tryptophan and gamma-aminobutyric acid (GABA) were either enriched or depleted in patients with major depression [35]. In particular, tryptophan metabolic pathways have been shown to be widely distributed across human gut bacterial species [35]. Intriguingly, the majority of these gut bacterial species with neuroactive potential are also found to be residents of the oral cavity [25]. However, to what extent these bacterial species can truly biosynthesize neurotransmitters within the host, either in the gut or the oral cavity, remains unknown. Thus, utilization of metabolomics

offers a functional readout of both host and microbial phenotypes encoded in the genome [38,39], and in conjunction with microbiome analyses, can provide mechanistic insights, yet current knowledge is greatly limited. In particular, microbial specialized metabolites have been shown to be canonical mediators of microbe-microbe and microbe-host interactions, and the most predominant specialized metabolites are of great interest for understanding the mechanisms of these interactions at the molecular level [38–40]. In this regard, the vast and highly diverse array of short peptides shown to play key roles in bacterial cell signaling [41], immune modulation, and neuroactive metabolism [42–44] remains largely unexplored. A recent study has shown that depletion of a variety of structurally uncharacterized dipeptides are associated with inflammatory bowel disease, a chronic inflammatory condition of the gastrointestinal tract [45]. These observations prompted us to hypothesize that neurotransmitters and dipeptides likely have pivotal roles in obesity-inflammation-depression interrelationships.

In this study we aimed to investigate whether oral microbiota and small-molecule mediators of key microbe-microbe and microbe-host interactions differ by depressive symptomatology and obesity as well as their co-occurrence, and are influenced by inflammatory processes. We performed 16S rRNA gene-based sequencing of the oral microbiome and untargeted mass spectrometry of small-molecules from saliva, as well as host inflammation regulation profiles in blood from 60 participants.

Methods

Participants

162 A total of 60 lean to obese participants (20-65 years old) with a range of subclinical depressive
163 symptoms, participating in a larger study investigating the impact of obesity on vascular
164 inflammation and immune cell activation in normotension versus stage 1 hypertension (Basal
165 systolic blood pressure (BP): 130-140 mmHg and diastolic BP: 80-90 mmHg), were included in
166 this study and provided saliva samples. Participant inclusion/exclusion criteria were previously
167 described in detail [33]. Briefly, participants were excluded if they had diabetes, recent history of
168 smoking or substance abuse, history of cardiovascular disease, history of bronchospastic
169 pulmonary disease, inflammatory disorders or health-related factors affecting immune function,
170 psychosis, major depressive disorder, and stage 2 clinical hypertension or with average BP
171 $\geq 145/90$ mmHg measured at the lab visit from six measurements on two separate days, using a
172 Dinamap Compact BP monitor (Critikon, Tampa, FL). Sociodemographic characteristics (i.e.,
173 age, sex, and race) and anthropometrics (i.e., height, weight, hip and waist circumference) data
174 were collected.

175 **Obesity characterization**

176 BMI was calculated based on height and weight measurements (kg/m^2), and individuals were
177 dichotomized into two groups, based on our prior findings of little notable differences in
178 inflammatory or depressive symptoms state between lean and overweight individuals (ref): non-
179 obese ($\text{BMI} < 30 \text{ kg/m}^2$) and obese ($\text{BMI} \geq 30 \text{ kg/m}^2$). For further adiposity characterization dual
180 x-ray absorptiometry was performed to calculate %total and trunk body fat.

181 **Depressive symptomatology assessment**

Depressive symptoms were assessed using the Beck Depression Inventory (BDI-Ia), a comprehensive and clinically robust self-report 21-item questionnaire (Beck et al., 1996). Each question was scored from 0-3, summed to a BDI total score (BDI-T), and then subcategorized into cognitive-affective (BDI-C) and somatic (BDI-S) depression scores based on the items such as BDI-C: guilt, pessimism and BDI-S: fatigue, sleep disruption [46].

Based on obesity status and mean BDI-T scores, participants were categorized into 4-groups: non-obese and lower-depressive controls (N=10 participants; n=43 samples; “controls”), obese and lower-depressive (N=18; n=74; “Ob/lower-Dep”), non-obese and higher-depressive symptoms (N=5; n=22; “Non-ob/higher-Dep”), and obese and higher-depressive symptoms (N=27; n=122; “Ob/higher-Dep”).

Blood collection and cellular inflammation assay

For detailed protocol, see Supplementary Materials and Methods section. Briefly, LPS-stimulated blood was incubated with beta-adrenergic receptor agonist isoproterenol and evaluated for intracellular monocyte TNF- α production using flow cytometry, as previously described [47]. Monocyte beta-adrenergic receptor-mediated inflammation control (i.e., “BARIC”, a measure of systemic inflammation) was calculated as the arithmetic difference in %TNF- α -producing monocytes between LPS + media-treated and LPS + isoproterenol-treated samples.

Saliva collection, DNA extraction and 16S sequencing

201 For detailed protocols of saliva collection procedure and 16S analysis, see Supplementary
202 Materials and Methods section. Saliva from each participant was collected at five time points
203 across a single day: waking, mid-morning (10:00 hrs), midday (12:00 hrs), afternoon (14:00 hrs),
204 and evening (17:00 hr).

205 **Statistical analyses**

206 Statistical analyses were conducted using R software (version 3.6.3) in RStudio (version
207 1.2.5019). First, associations among continuous and categorical metadata variables i.e., age,
208 obesity (BMI, %total body fat and trunk fat), BARIC, BDI scores (BDI-T, BDI-C and BDI-S)
209 were assessed using univariate Spearman correlations across all participants using *psych* package
210 in R software. We applied a simple linear mixed-effects model (LMM) fit to model two alpha
211 diversity measures (Shannon index and Faith's PD) using restricted maximum likelihood
212 (REML) with a random intercept by participant to account for repeated measurements across the
213 day, and main effects of obesity status, depressive symptom status, and BARIC. Age, sex, race
214 were included as covariates in the model. Beta-diversity between groups was tested using non-
215 parametric *PERMANOVA* with 999 permutations constrained by participant to adjust for 3-5
216 samples per participant, and a test of homogeneity of dispersion was conducted with the same
217 constraints using *PERMDISP2* in *vegan* package to test overall species composition differences
218 within the groups. Next, post-hoc pairwise comparison was performed using *pairwiseAdonis*.

219 **Random forest classifications**

220 A random forest sample classifier was trained based on the 16S data with tuned hyperparameters
221 (num.trees=500, mtry=45) in the 20-time repeated, stratified 5-fold cross-validation using *caret*
222 package in R software. The dataset was repeatedly split into five groups with similar class
223 distributions, and we trained the classifier on 80% of the data, and made predictions on the
224 remaining 20% of the data in each fold iteration. We next evaluated the performance of the
225 classifier on predicting the four groups (i.e. controls, Ob/lower-Dep, Non-ob/higher-Dep,
226 Ob/higher-Dep) using both area under the receiver operating characteristic curve (AUROC) and
227 area under the precision-recall curve (AUPRC) based on the samples' predictions in the holdout
228 test set using *PRROC* package in R. To account for multiple samples per-participant, we next
229 performed 20-time repeated group 3-fold cross-validation, where each participant is in a different
230 testing fold and also samples from the same subjects are never in both testing and training folds.

231 **Small molecule metabolite detection through mass spectrometry**

232 Saliva was dried and resuspended in 80% MeOH–20% water and submitted to untargeted
233 LC/MS/MS analysis. For a detailed protocol, see Supplementary Materials and Methods section.
234 To examine the metabolic potential in the oral ecosystem and understand the intimate link
235 between salivary microbiota and metabolome in obesity-depressive symptom relationships, we
236 conducted untargeted liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis
237 of the saliva samples from the same participants who were first investigated for taxonomic
238 profiling in the above analyses [48,49]. By integrating feature based molecular networking
239 [50] with an automated chemical classification [51] and reference frame based differential

240 abundance analysis [52] approaches, we revealed differential representation of the key molecular
241 features in obesity and depressive symptom conditions.

242 **Feature based mass spectral molecular networking (FBMN) and chemically-informed** 243 **comparison of metabolomic profiles**

244 A data matrix of MS1 features that triggered MS2 scans were uploaded along with the metadata
245 file to Global Natural Product Social Molecular Networking (GNPS) (<https://gnps.ucsd.edu>)
246 [49]. Feature-based molecular networking (version release_20) [50] was performed, and library
247 IDs were generated (see Supplementary Materials and Methods section). To further gain a broad
248 overview of the chemistry of salivary metabolomes from MS/MS data, utilizing an automated
249 chemical classification approach [51], available via GNPS platform, we performed a chemically-
250 informed comparison of untargeted metabolomic profiles across the four groups.

251 **Differential ranking of taxa and metabolomic features**

252 Differential ranks of taxa and metabolomic features were calculated using Songbird [52], which
253 uses reference frames. Age, sex, race and time of day of saliva collection were provided as
254 covariates in generating a multinomial regression model based on microbial features.
255 Differential microbial features were visualized alongside *de novo* phylogenetic tree constructed
256 from the representative sequences of amplicon sequence variants (ASVs) obtained in this study
257 using EMPress [23]. Statistical significance was tested by applying LMMs on log-ratios of the
258 top-and bottom-20 ranked microbes for each group obtained using Qurro rank plots [53]. We
259 applied a linear regression model by utilizing log-ratios of bacterial features and BARIC

inflammatory scores to test interactions between obesity-depressive symptoms and inflammation relationships.

To mitigate the inter-batch effect often observed in the metabolomics data due to technical limitations in the number of samples processed in a batch, relative abundances were adjusted for batch specific-effect along with age, sex, race and time of day, utilizing the multivariate model in the reference frame-based approach [52]. We chose cluster 1 (90 features) as the denominator (“reference frame”) for the log-ratio calculations due to its high prevalence across samples, and moreover, GNPS analyses groups structurally similar molecules into a cluster. Statistical significance was tested by applying Friedman test to account for repeated measurements, prior to multiple pairwise comparison analysis using Wilcoxon rank-sum tests.

Microbe-metabolite interactions through their co-occurrence probabilities

Permutation based differential abundance testing was performed using discrete false-discovery rate correction method [54] in Calour (<https://github.com/biocore/calour>) to remove batch-specific MS1 molecular features. Annotated features that were not identified as batch-specific were included in the co-occurrence analysis. Using ASV (N=1516) and annotated molecular features (N=155) as inputs to train neural networks [55] in QIIME 2 [56], we estimated the conditional probability that each molecule is present given the presence of a specific microorganism. The resulting conditional probability matrix representing microbe-metabolite interactions was visualized as an EMPPeror biplot [55].

Results

Participant characteristics

A total of 261 saliva samples collected from five time points across the day from 60 participants were analyzed (20 – 65 years): 50 participants had five; 51 had four, and 54 had three samples which were adjusted in analyses (See Statistical Analyses). Participants were categorized into the following four groups: non-obese (BMI <30 kg/m²) and lower-depressive controls (N=10 participants; n=43 saliva samples; “controls”), obese (BMI ≥30 kg/m²) and lower-depressive (N=18; n=74; “Ob/lower-Dep”), non-obese and higher-depressive symptoms (N=5; n=22; “Non-ob/higher-Dep”), and obese and higher-depressive symptoms (N=27; n=122; “Ob/higher-Dep”). Sociodemographic characteristics are presented across participant groups (Table 1).

Obesity is associated with depressive symptomatology and inflammation

Given that individuals with a clinical diagnosis of depression and/or use of antidepressants were excluded from the study to focus on inflammation-related subclinical depressive symptoms in relation to obesity among otherwise healthy adults, BDI total scores (BDI-T) on average were low (median=3; sd=5; range=0-22). The median value of BDI-T of ≥3 was used to divide participants with relatively ‘higher’ or ‘lower’ depressive symptoms in this non-clinical sample.

In all individuals, BMI was positively correlated with BDI-T scores ($r=0.29$, $p=0.04$), as well as cognitive-affective ($r=0.27$, $p=0.03$) and somatic symptom scores with small to medium effects ($r=0.22$, $p=0.08$) (Figure S1). BARIC values, an indicator of neuro-inflammation regulation, were negatively correlated with BMI ($r=-0.38$, $p=0.009$), and an estimation of adipose tissue volume indicated by %trunk fat ($r=-0.25$, $p=0.034$) across all participants (Figure S1). Age did not moderate any of these relationships, which is in agreement with previous

findings [20]. Altogether, obesity was significantly associated with both inflammation regulation and depressive symptoms. However, no significant associations were observed between BARIC and BDI scores in this study (Figure S1).

Oral microbiota differ based on obesity-depressive symptom groups and inflammation status

Principal coordinates analysis (PCoA) and post-hoc pairwise comparisons of unweighted-UniFrac distances of samples revealed that oral microbiota composition was distinct by obesity (PERMANOVA pseudo-F=0.004, $p=0.001$, Figure 1A, Table 2), BDI-T (PERMANOVA pseudo-F=0.001, $p=0.0$, Figure 1B, Table 2) and across the four obesity-depressive symptom comorbid groups (i.e, Ctrl, Ob/lower-Dep, Non-ob/higher-Dep, Ob/higher-Dep) (Figure 1C, Table 2 and Table 3). Beta-diversity was also significantly differentiated based on the host inflammation across all participants (PERMANOVA pseudo-F=4.71, $p<0.001$, Figure 1D and Table 2). Significant beta-diversity differences were also observed by age, sex, and race but not by sampling time of day (Table 2). Phylogenetic alpha-diversity increased with inflammation (Faith's PD: $t=-2.312$, $p=0.025$). Inflammation had slightly larger effects ($R^2=0.02$) on microbiome composition than obesity ($R^2=0.008$) and depressive symptomatology ($R^2=0.01$) (Table 2).

Oral microbiota is predictive of the host obesity-depressive symptomatology

To assess the predictive capacity of the oral microbiome in stratifying individuals with depressive symptoms, obesity and depressive symptomatology-obesity co-occurrence status, we

utilized supervised random forest classification. The prediction performance of the model indicated by both area under the receiver operating characteristic curve (AUROC) and area under precision recall curve (AUPRC), revealed high prediction accuracy (AUROC=0.75 and AUPRC=0.74) for obesity-depressive symptom status (Ob/higher Dep) than other groups when multiple samples per-participant were taken into account (Figure 2A and 2B). The Ctrl group was predicted with AUROC=0.75 and AUPRC=0.58; Ob/lower Dep status with AUROC=0.70 and AUPRC=0.49; Non-ob/higher Dep with AUROC=0.70 and AUPRC=0.46. However, at sample-level both AUROC and AUPRC ranged from 0.93 to 0.97, across all groups (Figure S2A and S2B). Altogether, oral microbiome was highly predictive of depressive symptomatology-obesity co-occurrences than obesity and depressive symptomatology independently.

Key oral bacterial taxa are associated with specific host phenotype

Next, we identified the most differentially ranked microbes (99 unique taxa) associated with host phenotypes (Figure 2C). Linear mixed-effects model revealed significant differences in the relative abundances of microbes associated with Ob/higher-Dep ($t=6.5$, $p=5.07e-08$), Non-ob/higher-Dep ($t=-4.2$, $p=0.0002$) and Ob/lower Dep ($t=-4.5$, $p=5.07e-05$) in comparison to Ctrl group, and with inflammation status ($t=-4.83$, $p=3.03e-05$). Most differentially represented taxa (84 unique taxa) were assigned to Gram-negative bacteria such as *Prevotella*, *Aggregatibacter*, *Pseudomonas*, *Campylobacter*, Clostridia (*Selenomonas*, *Butyrivibrio*, *Veillonella*, *Megasphaera* and *Schwartzia*), *Leptotrichia*, *Capnocytophaga*, and periodontal pathogens such as *Treponema*, *Veillonella*, *Porphyromonas* and *Fusobacterium*. Gram-positive (15 unique taxa) were assigned to Peptostreptococcaceae, Clostridia (*Catonella*,

343 Mogibacteriaceae), *Staphylococcus*, *Corynebacterium*, *Rothia*, *Actinomyces*, and
344 beneficial/probiotic genera *Bifidobacterium* and *Lactobacillus* (Figure 2C, log-fold change
345 abundances for each microbe are shown in Table S1). The Ob/higher-Dep group exhibited a
346 slightly higher abundance of Gram-negative bacteria relative to Gram-positive compared to the
347 Ctrl group (Wilcoxon test: $p=0.004$) (Figure 2D), which were not significantly associated with
348 BARIC scores (data not shown).

349 **Small molecules detected in saliva are associated with obesity-depressive symptom-** 350 **inflammation relationships**

351 Untargeted LC-MS/MS analysis of the saliva samples was performed to examine the metabolic
352 potential in the oral ecosystem and understand the intimate link between salivary microbiota and
353 metabolome in obesity-depressive symptom relationships.

354 The most predominant chemical classes identified from automated chemical
355 classification [51] of our samples via GNPS [49] platform were terpenoids, indoles,
356 carbohydrates and carbohydrate conjugates, amino acids, peptides, derivatives of purines and
357 pyrimidines, eicosanoids and linoleic acids (Figure S3). Particularly, molecular structures of
358 diazines, benzotriazoles, imidazopyrimidines and azides were batch-specific (Figure S3).
359 Feature-based mass spectral molecular networking of 7,818 total MS1 molecular features (which
360 included retention time and relative quantitative information) enabled the annotation of 248 that
361 had matches against all publicly available reference spectra [57]. It should be noted that these are
362 level 2 or 3 annotations according to the 2007 metabolomics standards initiative [58]. A
363 reference-frame based approach enabled the identification of 155 features distinctly associated

364 with specific categories relative to Ctrl group (i.e., Non-Ob/lower-dep) (Figure 3). Key
365 molecules involved in host-microbiota interactions such as the annotation as tyrosine (level 2), a
366 precursor of catecholamine, dopamine and serotonin, and tryptophan (level 2, cluster 14 and 26
367 in Figure 3), a precursor of the neurotransmitter serotonin, were depleted in Ob/higher-Dep and
368 Ob/lower-Dep groups (Figure 2B). The amino acid, phenylalanine (Level 2, cluster 2 Figure 3), a
369 biosynthetic precursor of tyrosine, catecholamine, dopa and dopamine was less abundant in the
370 Ob/higher-Dep and Non-ob/higher-Dep groups, but increased with inflammation status (Figure
371 4A).

372 Within the molecular network, we also identified 41 molecular clusters primarily
373 associated with quorum sensing molecules of microbiota, products of microbial transformation
374 of dietary components or host molecules, and essential aromatic amino acids (Figure 3). Most
375 intriguingly, we identified 34 structurally distinct dipeptides across groups, making it the most
376 prevalent molecular cluster within the network (molecular features of clusters 2, 3, 5, 9, 12, 17,
377 19, 30, 31, 32 and 34 in Figure 3). Of these, molecular features of cluster 2 (present in 60
378 participants) were differentially represented in Ob/higher-Dep and Non-ob/higher-Dep
379 individuals, while features of cluster 34 (present in 58 participants) were differentially
380 represented in Ob/higher-Dep and Ob/lower Dep individuals, when compared to controls (see
381 left panels in Figure 4A). Moreover, clusters 2, 14 and 26 were depleted in the Ob/higher-Dep
382 and non-ob/higher-Dep groups, while cluster 34 was depleted in the Ob/higher-Dep and
383 Ob/lower Dep groups. Other differentially represented molecular clusters included clusters 14
384 (detected in 56 participants) and 26 (detected in 58 participants), which encompassed two of the
385 essential aromatic amino acids i.e. tryptophan and tyrosine molecules (see clusters 14 and 26 in

386 Figure 3, Figure 4A). Molecular features from these clusters are positively associated with
387 inflammation (right panels in Figure 4A). Abundance of features from the remaining clusters did
388 not significantly vary across groups (data not shown). Other molecular features included
389 previously reported microbiota-derived dipeptides (Phe-Val and Tyr-Val) (see clusters 2 and 30
390 in Figure 3) [42,59,60]. Dipeptide (Phe-Phe) reported to be synthesized by *Clostridium* (cluster 2
391 Figure 3) [61] was predominant in the Ob/higher-Dep group. Other molecules such cyclic
392 dipeptides (Val-Pro and Val-Leu), commonly found to be made by microbes, were also
393 identified (see cluster 2 and 12 Figure 3, Figure 4A, Table S2) [59,60]. The majority of the other
394 dipeptides identified were potentially related to host dietary metabolism (i.e. enzymatic digest of
395 food proteins) [43,44]. Among these, Tyr-Leu, Phe-Leu and Ile-Tyr (cluster 2 Figure 3), were
396 significantly more abundant in the Ctrl group compared to the other Ob/higher-Dep and
397 Ob/lower-Dep groups (Figure 4A) among which, Tyr-Pro (cluster 34 Figure 3) was also depleted
398 (Figure 4A).

399 **Key oral microbes co-occurred with biosynthetic precursors of the neurotransmitters and** 400 **dipeptide signaling molecules**

401 Integration of the microbiome and metabolomics data revealed associations between oral
402 microbial metabolism and key oral microbes such as *Prevotella*, *Clostridia*, *Selenomonas*,
403 *Aggregatibacter*, *Oribacterium*, *Corynebacterium*, and periodontal pathogens such as *Tannerella*
404 and *Porphyromonas* (Figure 4B). Dipeptide signaling molecules (Phe-Phe, Phe-Val and Tyr-Val)
405 co-occurred with *Clostridia*, *Prevotella* and *Porphyromonas*, corroborating known associations
406 of dipeptides produced by *Clostridium* spp. [42,59–61]. Members of *Clostridia* also co-occurred

407 with phenylalanine, a potential biosynthetic precursor of dopamine, epinephrine and tryptophan.
408 Intriguingly, *Oribacterium* belonging to *Clostridium* and *Tannerella* co-occurred with
409 tryptophan, shown to encompass tryptophan biosynthetic pathways. Our findings further
410 corroborate known microbial-derived cyclic dipeptides (Val-Leu and Val-Pro) associations with
411 *Selenomonas*, *Aggregatibacter* and *Clostridium* spp. (Figure 4B) [59,60]. Potential dietary
412 dipeptides (Phe-Leu, Tyr-Pro and Tyr-Leu) co-occurred with *Tannerella*, *Selenomonas*,
413 *Prevotella*, *Porphyromonas* and *Clostridia* [43,44].

414 **Discussion**

415 We previously reported that obesity is significantly associated with both inflammation and
416 depressive symptoms [20,21,47]. Growing evidence also suggests that gut bacterial composition
417 and their specialized metabolites may trigger chronic systemic inflammation in obesity-
418 depression co-occurrences [2], highlighting the importance of the host immune and microbial
419 interplay. In this study, we showed that the composition of salivary microbiota differ in co-
420 occurring obesity-depressive symptoms and in relation to obesity, depression, and inflammation.
421 We also showed that individual bacterial taxa were linked to specific host obesity-depressive
422 symptoms ‘phenotype’, and small-molecule mediated microbe-microbe and microbe-host
423 interactions likely play a critical role in these host phenotypes. While effects of obesity,
424 inflammation and depression phenotypes on gut microbiome have been studied previously, this
425 study extends our previous work [33] that identified relationships between oral microbial
426 composition, host stress profile and inflammatory status, by providing further evidence that oral
427 microbial composition and metabolic profiles are also influenced by the specific host

phenotypes, and are likely characterized by significant alterations in the biosynthetic precursors of neurotransmitters and signaling dipeptides. These findings highlight a potential link between oral microbiota and the brain (i.e. oral-brain axis), adding to known gut microbiota-brain interactions [34–36], as well as biomarker utility of oral microbiome in studying brain and behavioral outcomes.

Examining the composition of the oral microbiome revealed significant differences based on obesity, depressive symptomatology and comorbid obesity-depressive symptomatology. At the same time, the oral microbiome composition differed by the host inflammatory processes beyond the effects of obesity or depression. This emphasizes the need of further scrutinizing the central role of microbiome-mediated inflammation in obesity-depressive symptomatology interrelationship and is closely aligned with the existing literature in chronic low-grade inflammation at the intersection of depression and obesity.

Random forest classification indicated that oral microbiota is highly predictive of obesity-depressive symptom co-occurrences, suggesting specific microbial signatures associated with obesity-depression co-occurrences. Corroborating these findings, abundances of several microbes were differentially represented across the obesity-depressive symptomatology groups as revealed by the differential abundance analysis. Gram-negative microbes have been shown to be associated with inflammation due to their LPS cell wall, the hallmark trait of Gram-negative bacteria. We found that Gram-negative microbes *Prevotella*, *Aggregatibacter*, *Pseudomonas*, *Campylobacter*, *Selenomonas*, *Leptotrichia*, *Capnocytophaga*, and Gram-negative periodontal pathogens such as *Treponema*, *Veillonella*, *Porphyromonas* and *Fusobacterium* are enriched in Ob/higher-dep group. However, we found no significant correlation with BARIC scores that

450 measured monocytes' responsiveness to a β -AR agonist during an inflammatory response to LPS,
451 indicating inflammation regulatory processes [47]. Increased abundance of *Prevotella* in the
452 human oral cavity has been previously ambiguously associated with both health and disease
453 conditions [26,62,63]. Pathogenic *Campylobacter* has been shown to increase anxiety-like
454 behavior in mice [64] and *Aggregatibacter* has been reported to be associated with inflammation.
455 Notably, Gram-positive beneficial microbes *Bifidobacterium* and *Lactobacillus* depleted in
456 Ob/higher-Dep group are in line with their activity as they are reported to exhibit antidepressant
457 and anti-obesity effects, and reduced levels of TNF- α in both clinical and animal studies [65–67].
458 All of these differentially abundant oral taxa present potential biomarkers in obesity-depression
459 co-occurrences, however, more studies are needed to further confirm these findings, as our study
460 did not find significant differences in the abundances of microbes at genera-level.

461 We also found differences in relative abundance patterns in many molecules across the
462 obesity-depression symptoms groups, including quorum sensing molecules of microbiota,
463 products of microbial transformation of dietary components or host molecules and aromatic
464 amino acids. Importantly, metabolites of aromatic amino acids tryptophan and tyrosine, both of
465 which are precursors of the neurotransmitter serotonin, have been mechanistically implicated in
466 obesity-depression associations [68], and play signaling roles in host-microbe interactions in the
467 gut [69], were depleted in obese individuals compared to the control group. Host dietary
468 dipeptides (Tyr-Leu and Phe-Leu) that were significantly less abundant among the obese
469 individuals compared to the control group in this study are shown to display anti-depressant-like
470 activity as greater abundance of Tyr-Leu activates serotonin, dopamine and gamma aminobutyric
471 acid (GABA) receptors in mice [43,44]. Tyr-Pro and Ile-Tyr, which were also depleted in the

obese individuals in our study, are an inhibitor of angiotensin I-converting enzyme (ACE) with antihypertensive activity [70] and affect catecholamine (e.g. dopamine and noradrenaline) metabolism in the mouse brain [71], respectively. These findings offer initial mechanistic insight into comorbid obesity and depression, albeit complex.

Furthermore, we identified several structurally distinct dipeptides that were positively associated with inflammation. To our knowledge, it is the first time that microbial-derived dipeptide (Phe-Val, Tyr-Val and Phe-Phe) and cyclic dipeptides signaling molecules (Val-Pro and Val-Leu) were detected in salivary metabolomes. Biosynthetic gene clusters and the production of dipeptides (Phe-Val and Tyr-Val) have been recently identified in the human microbiome [42,59,60]. These molecules are known to play key roles in quorum sensing (cell-to-cell communication to maintain cell density) and virulence, and promote growth of beneficial *Bifidobacterium* [41]. A previous study showed that Phe-Phe derived from *Clostridium sp.* can inhibit host proteins by chemical modification of the host cellular proteins, especially by targeting cathepsins in human cell proteomes [61]. Given our findings that Phe-Phe was highly abundant in the Ob/higher-Dep group, its biological role in the cellular inflammatory process which likely underlie obesity-depression comorbidity warrants further investigation.

Our findings of specific microbe-metabolite interactions with potential to influence host's brain functioning offer potentially significant insight into the role of host immune-microbiome interplay in comorbid obesity-depression and is likely through microbial neurotransmitters. Metabolic pathways for biosynthesis of neuroactive molecules in the genomes of human-associated genera *Clostridium* and *Tannerella* have been recently reported [35]. Intriguingly, members of *Clostridium* and *Tannerella* co-occurred with tryptophan and have been

detected/reported to harbor genes for tryptophan biosynthesis [35]. Members of Clostridia co-occurred with phenylalanine, a potential biosynthetic precursor of dopamine, epinephrine and tryptophan, have been shown to be key species in neuropsychiatric disorders and shown to produce dopamine in mice [36,72]. Many of these molecules including the dipeptides, shown to have potential to cross the intestinal barrier and blood brain barrier, may modulate the oral–brain connection through neurotransmitter signaling pathways [35,72]. Such neurotransmitters and their biosynthetic precursors may offer promising targets for therapeutics.

There is a caveat in this study that merits caution: in an effort to recruit individuals with subclinical levels of depressive mood co-occurring with a range of obesity without antidepressant intake or heterogeneous clinical depression, the participants exhibited low levels of BDI scores on average which may limit the applicability of our findings to clinical depression. At the same time, it is notable that host-microbiome-metabolome signatures and their interactions appear to be salient in pathophysiology of subclinical depression symptomatology. We also acknowledge a small sample size of the study participants, in spite of the expanded specimen sample size owing to multiple saliva collections.

Conclusions

Despite these limitations, our study significantly expands the evidence for microbial specialized metabolites and peptides with neuroactive potential, adding further research avenues into microbiome-host physiology interactions and there is a great deal of clinical potential in understanding and modifying these interactions. Furthermore, it provides initial evidence for a

514 foundation of the microbial oral-brain axis in addition to the gut-brain axis in the context of
515 obesity-depression-inflammation interrelationships.

516 **Declarations**

517 **Ethics approval and consent to participate**

518 All participants provided informed consent to the protocol prior to the commencement of the
519 study. The Ethics Committee of the University of California, San Diego, CA, USA, approved the
520 study design as well as the procedure for obtaining informed consent (IRB reference number:
521 171027). All experiments were performed in accordance with the approved guidelines of UCSD
522 Human Research Protections Program.

523 **Consent for publication**

524 Not applicable

525 **Availability of data and material**

526 Sample metadata, the raw and processed 16S sequencing data and their associated feature tables,
527 and preparation metadata are available in Qiita Study ID 11259
528 (<https://qiita.ucsd.edu/study/description/11259>). Mass spectral files and LC-MS/MS preparation
529 metadata are accessible from the MassIVE repository accession ID MSV000083077
530 (<ftp://massive.ucsd.edu/MSV000083077>). The GNPS feature based molecular networking job is

531 available at [https://gnps.ucsd.edu/ProteoSAFe/status.jsp?](https://gnps.ucsd.edu/ProteoSAFe/status.jsp?task=f192a0030f694224a0ba8f08223a1323)
532 [task=f192a0030f694224a0ba8f08223a1323](https://gnps.ucsd.edu/ProteoSAFe/status.jsp?task=f192a0030f694224a0ba8f08223a1323)

533 **Competing interests**

534 PCD serves as a scientific advisor to Sirenas, Cybele and Galileo. PCD is also a founder and
535 scientific advisor of Ometa and Enveda with approval by UC San Diego.

536 **Funding**

537 This work was supported in part by R01 HL90975 and 90975S1 from the NIH (Hong), a Seed
538 Grant from the Center for Microbiome Innovation at UC San Diego (Hong), Wayne State
539 University Endowment Fund (Hong), and the Kavli Institute for Brain and Mind (KIBM)
540 Innovative Research Grant (Aleti).

541 **Authors' contributions**

542 Hong designed and obtained funding for the study. GA performed the data analysis. JNK, KW,
543 AT, ADS and Huang assisted with the data analysis. GA, Hong, PCD, ADS and RK interpreted
544 the results. GA, ET and Hong wrote the original manuscript. GA, JNK, ET, KW, AT, Huang,
545 ADS, Hong, PCD and RK reviewed and edited the manuscript.

546 **Acknowledgements**

547 Not applicable

References

1. Smith DJ, Court H, McLean G, Martin D, Martin JL, Guthrie B, et al. Depression and multimorbidity: A cross-sectional study of 1,751,841 patients in primary care. *J Clin Psychiatry. Physicians Postgraduate Press Inc.*; 2014;75:1202–8.
2. Schachter J, Martel J, Lin CS, Chang CJ, Wu TR, Lu CC, et al. Effects of obesity on depression: A role for inflammation and the gut microbiota. *Brain. Behav. Immun. Academic Press Inc.*; 2018. p. 1–8.
3. James SL, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 Diseases and Injuries for 195 countries and territories, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017. *Lancet. Lancet Publishing Group*; 2018;392:1789–858.
4. Mannan M, Mamun A, Doi S, Clavarino A. Is there a bi-directional relationship between depression and obesity among adult men and women? Systematic review and bias-adjusted meta analysis. *Asian J. Psychiatr. Elsevier B.V.*; 2016. p. 51–66.
5. Dawes AJ, Maggard-Gibbons M, Maher AR, Booth MJ, Miake-Lye I, Beroes JM, et al. Mental health conditions among patients seeking and undergoing bariatric surgery a meta-analysis. *JAMA - J Am Med Assoc. American Medical Association*; 2016;315:150–63.
6. Pratt LA, Brody DJ. Depression and obesity in the U.S. adult household population, 2005-2010. *NCHS Data Brief. NCHS Data Brief*; 2014;1–8.
7. Luppino FS, De Wit LM, Bouvy PF, Stijnen T, Cuijpers P, Penninx BWJH, et al. Overweight, obesity, and depression: A systematic review and meta-analysis of longitudinal studies. *Arch. Gen. Psychiatry. Arch Gen Psychiatry*; 2010. p. 220–9.
8. Woo YS, Seo HJ, McIntyre RS, Bahk WM. Obesity and its potential effects on antidepressant treatment outcomes in patients with depressive disorders: A literature review. *Int. J. Mol. Sci. MDPI AG*; 2016.
9. Scully T. Public health: Society at large. *Nature. Nature Publishing Group*; 2014;508:S50–1.
10. Capuron L, Lasselin J, Castanon N. Role of Adiposity-Driven Inflammation in Depressive Morbidity. *Neuropsychopharmacology. Nature Publishing Group*; 2017. p. 115–28.
11. Milano W, Ambrosio P, Carizzzone F, De Biasio V, Di Munzio W, Foia MG, et al. Depression and Obesity: Analysis of Common Biomarkers. *Diseases. MDPI AG*; 2020;8:23.

- 579 12. Young JJ, Bruno D, Pomara N. A review of the relationship between proinflammatory
580 cytokines and major depressive disorder. *J. Affect. Disord. Elsevier B.V.*; 2014. p. 15–20.
- 581 13. Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease.
582 *Nat. Rev. Immunol. Nat Rev Immunol*; 2011. p. 85–97.
- 583 14. Dalmas E, Clément K, Guerre-Millo M. Defining macrophage phenotype and function in
584 adipose tissue. *Trends Immunol. Trends Immunol*; 2011. p. 307–14.
- 585 15. Wohleb ES, McKim DB, Sheridan JF, Godbout JP. Monocyte trafficking to the brain with
586 stress and inflammation: A novel axis of immune-to-brain communication that influences mood
587 and behavior. *Front. Neurosci. Frontiers Media S.A.*; 2015.
- 588 16. Miller AH, Raison CL. The role of inflammation in depression: From evolutionary
589 imperative to modern treatment target. *Nat. Rev. Immunol. Nature Publishing Group*; 2016. p.
590 22–34.
- 591 17. Osimo EF, Pillinger T, Rodriguez IM, Khandaker GM, Pariante CM, Howes OD.
592 Inflammatory markers in depression: A meta-analysis of mean differences and variability in
593 5,166 patients and 5,083 controls. *Brain. Behav. Immun. Academic Press Inc.*; 2020. p. 901–9.
- 594 18. Milaneschi Y, Lamers F, Berk M, Penninx BWJH. Depression Heterogeneity and Its
595 Biological Underpinnings: Toward Immunometabolic Depression. *Biol. Psychiatry. Elsevier*
596 *USA*; 2020. p. 369–80.
- 597 19. Hong S. Inflammation at the interface of physical and neuropsychiatric outcomes:
598 Investigation of neuroendocrine regulatory pathways to inform therapeutics. *Brain. Behav.*
599 *Immun. Academic Press Inc.*; 2020. p. 270–4.
- 600 20. Kohn JN, Cabrera Y, Dimitrov S, Guay-Ross N, Pruitt C, Shaikh FD, et al. Sex-specific roles
601 of cellular inflammation and cardiometabolism in obesity-associated depressive
602 symptomatology. *Int J Obes. Nature Publishing Group*; 2019;43:2045–56.
- 603 21. Cheng T, Dimitrov S, Pruitt C, Hong S. Glucocorticoid mediated regulation of inflammation
604 in human monocytes is associated with depressive mood and obesity.
605 *Psychoneuroendocrinology. Elsevier Ltd*; 2016;66:195–204.
- 606 22. Sharma S, Fulton S. Diet-induced obesity promotes depressive-like behaviour that is
607 associated with neural adaptations in brain reward circuitry. *Int J Obes. Int J Obes (Lond)*;
608 2013;37:382–9.
- 609 23. Schneeberger M, Everard A, Gómez-Valadés AG, Matamoros S, Ramírez S, Delzenne NM,
610 et al. *Akkermansia muciniphila* inversely correlates with the onset of inflammation, altered

adipose tissue metabolism and metabolic disorders during obesity in mice. *Sci Rep. Nature Publishing Group*; 2015;5.

24. Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, et al. Metabolic endotoxemia initiates obesity and insulin resistance. *Diabetes*. *Diabetes*; 2007;56:1761–72.

25. Chen T, Yu WH, Izard J, Baranova O V., Lakshmanan A, Dewhirst FE. The Human Oral Microbiome Database: a web accessible resource for investigating oral microbe taxonomic and genomic information. *Database (Oxford)*. *Database (Oxford)*; 2010;2010.

26. Dewhirst FE, Chen T, Izard J, Paster BJ, Tanner ACR, Yu WH, et al. The human oral microbiome. *J Bacteriol*. *J Bacteriol*; 2010;192:5002–17.

27. Schmidt TSB, Hayward MR, Coelho LP, Li SS, Costea PI, Voigt AY, et al. Extensive transmission of microbes along the gastrointestinal tract. *Elife*. *eLife Sciences Publications Ltd*; 2019;8.

28. Atarashi K, Suda W, Luo C, Kawaguchi T, Motoo I, Narushima S, et al. Ectopic colonization of oral bacteria in the intestine drives TH1 cell induction and inflammation. *Science (80-)*. *American Association for the Advancement of Science*; 2017;358:359–65.

29. Dickson I. Gut microbiota: Oral bacteria: A cause of IBD? *Nat. Rev. Gastroenterol. Hepatol*. *Nature Publishing Group*; 2018. p. 4–5.

30. Dominy SS, Lynch C, Ermini F, Benedyk M, Marczyk A, Konradi A, et al. *Porphyromonas gingivalis* in Alzheimer’s disease brains: Evidence for disease causation and treatment with small-molecule inhibitors. *Sci Adv*. *American Association for the Advancement of Science*; 2019;5.

31. Farrokhi V, Nemati R, Nichols FC, Yao X, Anstadt E, Fujiwara M, et al. Bacterial lipodipeptide, Lipid 654, is a microbiome-associated biomarker for multiple sclerosis. *Clin Transl Immunol*. *John Wiley and Sons Inc*; 2013;2.

32. Shen L. Gut, oral and nasal microbiota and Parkinson’s disease. *Microb. Cell Fact*. *BioMed Central Ltd.*; 2020.

33. Kohn JN, Kosciolk T, Marotz C, Aleti G, Guay-Ross RN, Hong SH, et al. Differing salivary microbiome diversity, community and diurnal rhythmicity in association with affective state and peripheral inflammation in adults. *Brain Behav Immun*. *Academic Press Inc.*; 2020;87:591–602.

34. Yano JM, Yu K, Donaldson GP, Shastri GG, Ann P, Ma L, et al. Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis. *Cell*. *Cell Press*; 2015;161:264–76.

642 35. Valles-Colomer M, Falony G, Darzi Y, Tigchelaar EF, Wang J, Tito RY, et al. The
643 neuroactive potential of the human gut microbiota in quality of life and depression. *Nat*
644 *Microbiol.* Nature Publishing Group; 2019;4:623–32.

645 36. Olsen I, Hicks SD. Oral microbiota and autism spectrum disorder (ASD). *J. Oral Microbiol.*
646 Taylor and Francis Ltd.; 2020.

647 37. Olsen I. Update on bacteraemia related to dental procedures. *Transfus Apher Sci.* *Transfus*
648 *Apher Sci*; 2008;39:173–8.

649 38. Aleti G, Baker JL, Tang X, Alvarez R, Dinis M, Tran NC, et al. Identification of the bacterial
650 biosynthetic gene clusters of the oral microbiome illuminates the unexplored social language of
651 bacteria during health and disease. *MBio.* American Society for Microbiology; 2019;10:1–19.

652 39. Garg N, Luzzatto-Knaan T, Melnik A V., Caraballo-Rodríguez AM, Floros DJ, Petras D, et
653 al. Natural products as mediators of disease. *Nat. Prod. Rep.* Royal Society of Chemistry; 2017.
654 p. 194–219.

655 40. Donia MS, Fischbach MA. Small molecules from the human microbiota. *Science* (80-).
656 American Association for the Advancement of Science; 2015;349:1254766.

657 41. Hatanaka M, Morita H, Aoyagi Y, Sasaki K, Sasaki D, Kondo A, et al. Effective bifidogenic
658 growth factors cyclo-Val-Leu and cyclo-Val-Ile produced by *Bacillus subtilis* C-3102 in the
659 human colonic microbiota model. *Sci Rep.* Nature Research; 2020;10.

660 42. Cao L, Shcherbin E, Mohimani H. A Metabolome- and Metagenome-Wide Association
661 Network Reveals Microbial Natural Products and Microbial Biotransformation Products from the
662 Human Microbiota. *mSystems.* American Society for Microbiology; 2019;4.

663 43. Mizushige T, Uchida T, Ohinata K. Dipeptide tyrosyl-leucine exhibits antidepressant-like
664 activity in mice. *Sci Rep.* Nature Research; 2020;10.

665 44. Kanegawa N, Suzuki C, Ohinata K. Dipeptide Tyr-Leu (YL) exhibits anxiolytic-like activity
666 after oral administration via activating serotonin 5-HT1A, dopamine D1 and GABAA receptors
667 in mice. *FEBS Lett.* *FEBS Lett*; 2010;584:599–604.

668 45. Franzosa EA, Sirota-Madi A, Avila-Pacheco J, Fornelos N, Haiser HJ, Reinker S, et al. Gut
669 microbiome structure and metabolic activity in inflammatory bowel disease. *Nat Microbiol.*
670 Nature Publishing Group; 2019;4:293–305.

671 46. Beck AT, Steer RA, Ball R, Ranieri WF. Comparison of Beck depression inventories -IA and
672 -II in psychiatric outpatients. *J Pers Assess.* *J Pers Assess*; 1996;67:588–97.

673 47. Hong S, Dimitrov S, Cheng T, Redwine L, Pruitt C, Mills PJ, et al. Beta-adrenergic receptor
674 mediated inflammation control by monocytes is associated with blood pressure and risk factors
675 for cardiovascular disease. *Brain Behav Immun. Academic Press Inc.*; 2015;50:31–8.

676 48. Aron AT, Gentry EC, McPhail KL, Nothias LF, Nothias-Esposito M, Bouslimani A, et al.
677 Reproducible molecular networking of untargeted mass spectrometry data using GNPS. *Nat*
678 *Protoc. Nature Research*; 2020;15:1954–91.

679 49. Wang M, Carver JJ, Phelan V V., Sanchez LM, Garg N, Peng Y, et al. Sharing and
680 community curation of mass spectrometry data with Global Natural Products Social Molecular
681 Networking. *Nat. Biotechnol. Nature Publishing Group*; 2016. p. 828–37.

682 50. Nothias LF, Petras D, Schmid R, Dührkop K, Rainer J, Sarvepalli A, et al. Feature-based
683 molecular networking in the GNPS analysis environment. *Nat Methods. Nature Research*;
684 2020;17:905–8.

685 51. Tripathi A, Vázquez-Baeza Y, Gauglitz JM, Wang M, Dührkop K, Nothias-Esposito M, et al.
686 Chemically informed analyses of metabolomics mass spectrometry data with Qemistree. *Nat*
687 *Chem Biol. Nature Research*; 2021;17:146–51.

688 52. Morton JT, Marotz C, Washburne A, Silverman J, Zaramela LS, Edlund A, et al.
689 Establishing microbial composition measurement standards with reference frames. *Nat Commun.*
690 *Nature Publishing Group*; 2019;10.

691 53. Fedarko MW, Martino C, Morton JT, González A, Rahman G, Marotz CA, et al.
692 Visualizing’omic feature rankings and log-ratios using Qurro. *NAR Genomics Bioinforma.*
693 *Oxford University Press (OUP)*; 2020;2.

694 54. Jiang L, Amir A, Morton JT, Heller R, Arias-Castro E, Knight R. Discrete False-Discovery
695 Rate Improves Identification of Differentially Abundant Microbes. *mSystems. American Society*
696 *for Microbiology*; 2017;2.

697 55. Morton JT, Aksenov AA, Nothias LF, Foulds JR, Quinn RA, Badri MH, et al. Learning
698 representations of microbe–metabolite interactions. *Nat Methods. Nature Research*;
699 2019;16:1306–14.

700 56. Bolyen E, Rideout JR, Dillon MR, Bokulich NA, Abnet CC, Al-Ghalith GA, et al.
701 Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2. *Nat.*
702 *Biotechnol. Nature Publishing Group*; 2019. p. 852–7.

703 57. Aksenov AA, Da Silva R, Knight R, Lopes NP, Dorrestein PC. Global chemical analysis of
704 biology by mass spectrometry. *Nat. Rev. Chem. Nature Publishing Group*; 2017. p. 1–20.

705 58. Sumner LW, Amberg A, Barrett D, Beale MH, Beger R, Daykin CA, et al. Proposed
706 minimum reporting standards for chemical analysis: Chemical Analysis Working Group
707 (CAWG) Metabolomics Standards Initiative (MSI). *Metabolomics*. *Metabolomics*; 2007;3:211–
708 21.

709 59. Park HB, Crawford JM. Pyrazinone protease inhibitor metabolites from *Photorhabdus*
710 *luminescens*. *J Antibiot (Tokyo)*. Nature Publishing Group; 2016;69:616–21.

711 60. Wyatt MA, Mok MCY, Junop M, Magarvey NA. Heterologous Expression and Structural
712 Characterisation of a Pyrazinone Natural Product Assembly Line. *ChemBioChem*.
713 *Chembiochem*; 2012;13:2408–15.

714 61. Guo CJ, Chang FY, Wyche TP, Backus KM, Acker TM, Funabashi M, et al. Discovery of
715 Reactive Microbiota-Derived Metabolites that Inhibit Host Proteases. *Cell*. *Cell Press*;
716 2017;168:517-526.e18.

717 62. Zhang L, Liu Y, Zheng HJ, Zhang CP. The Oral Microbiota May Have Influence on Oral
718 Cancer. *Front Cell Infect Microbiol*. *Frontiers Media S.A.*; 2020;9.

719 63. Larsen JM. The immune response to *Prevotella* bacteria in chronic inflammatory disease.
720 *Immunology*. Blackwell Publishing Ltd; 2017. p. 363–74.

721 64. Goehler LE, Park SM, Opitz N, Lyte M, Gaykema RPA. *Campylobacter jejuni* infection
722 increases anxiety-like behavior in the holeboard: Possible anatomical substrates for
723 viscerosensory modulation of exploratory behavior. *Brain Behav Immun*. *Brain Behav Immun*;
724 2008;22:354–66.

725 65. Abildgaard A, Elfving B, Hokland M, Lund S, Wegener G. Probiotic treatment protects
726 against the pro-depressant-like effect of high-fat diet in Flinders Sensitive Line rats. *Brain Behav*
727 *Immun*. Academic Press Inc.; 2017;65:33–42.

728 66. Abildgaard A, Elfving B, Hokland M, Wegener G, Lund S. Probiotic treatment reduces
729 depressive-like behaviour in rats independently of diet. *Psychoneuroendocrinology*. Elsevier Ltd;
730 2017;79:40–8.

731 67. Schellekens H, Torres-Fuentes C, van de Wouw M, Long-Smith CM, Mitchell A, Strain C, et
732 al. *Bifidobacterium longum* counters the effects of obesity: Partial successful translation from
733 rodent to human. *EBioMedicine*. Elsevier B.V.; 2021;63.

734 68. Chaves Filho AJM, Lima CNC, Vasconcelos SMM, de Lucena DF, Maes M, Macedo D.
735 IDO chronic immune activation and tryptophan metabolic pathway: A potential

736 pathophysiological link between depression and obesity. *Prog. Neuro-Psychopharmacology Biol.*
737 *Psychiatry*. Elsevier Inc.; 2018. p. 234–49.

738 69. Roager HM, Licht TR. Microbial tryptophan catabolites in health and disease. *Nat. Commun.*
739 *Nature Publishing Group*; 2018.

740 70. Yamamoto N, Maeno M, Takano T. Purification and Characterization of an Antihypertensive
741 Peptide from a Yogurt-Like Product Fermented by *Lactobacillus helveticus* CPN4. *J Dairy Sci.*
742 *American Dairy Science Association*; 1999;82:1388–93.

743 71. Moriyasu K, Ichinose T, Nakahata A, Tanaka M, Matsui T, Furuya S. The Dipeptides Ile-Tyr
744 and Ser-Tyr Exert Distinct Effects on Catecholamine Metabolism in the Mouse Brainstem. *Int J*
745 *Pept. Hindawi Limited*; 2016;2016.

746 72. Asano Y, Hiramoto T, Nishino R, Aiba Y, Kimura T, Yoshihara K, et al. Critical role of gut
747 microbiota in the production of biologically active, free catecholamines in the gut lumen of mice.
748 *Am J Physiol - Gastrointest Liver Physiol. Am J Physiol Gastrointest Liver Physiol*; 2012;303.

749 **Figures**

750 **Figure 1.** Principal coordinates analyses (PCoA) of oral bacterial communities in (A) non-obese
751 and obese (B) low depressive and higher depressive (C) non-obese low-depressive, non-obese
752 high-depressive, obese, and co-occurring obesity and depressive symptom groups, and (D) in
753 inflammation status. Unweighted-UniFrac distances among samples were visualized using
754 EMPeror. Significance of separation between the groups and further post-hoc pairwise
755 comparisons between groups was tested by applying PERMANOVA test on the principal
756 coordinates.

757 **Figure 2.** Oral microbiota is distinctly impacted by the host status in co-occurring obesity-
758 depressive status. (A) Receiver operating characteristic curves (AUROC) illustrating
759 classification accuracy of the random forest model across all groups (i.e. controls, Ob/lower Dep,
760 Non-ob/higher-Dep, Ob/higher-Dep). (B) Area under precision recall curves (AUPRC)
761 illustrating performance of the random forest model across all groups. (C) Phylogenetic
762 distribution of the most differentially ranked taxa across the groups. Branches of the *de novo*
763 phylogenetic tree and the innermost ring are colored by phyla. Each barplot layer represents log-
764 fold change abundances of taxa within the group in comparison to the healthy controls i.e. Non-
765 ob/lower-Dep. A multinomial regression model was employed for regressing log-fold change
766 abundances against BARIC values. (D) Log-fold change abundances of Gram-negative microbes
767 relative to Gram-positive microbes across host phenotypes.

768 **Figure 3.** Feature-based molecular network of the ions detected in salivary metabolomes of
769 obese-depressive group. The molecular network was generated by 293 nodes with 41 molecular
770 clusters, which are sub-networks of a larger network generated via Global Natural Products
771 Social Molecular Networking (GNPS). Nodes (small circles with m/z values) represent unique
772 tandem mass spectrometry (MS/MS) consensus spectra and edges (lines) drawn between the
773 nodes correspond to similarity (cosine score) between MS/MS fragmentation. Annotation is
774 performed by MS/MS spectral library matching in GNPS platform. Pie charts within the
775 individual nodes qualitatively represent specific ion presence across groups: non-obese and non-
776 depressive, obese, depressive, and both obese and depressive symptom groups, as well as blank
777 samples. Molecular clusters 2, 3, 4, 5, 9, 17, 19, 30 and 34 represent structural diversity of
778 dipeptides. Molecular clusters 2, 14 and 26 represent aromatic amino acids tryptophan, tyrosine
779 and phenylalanine.

Pie chart colors

- Non-obese low-depressive
- Non-obese high-depressive
- Obese high-depressive
- Obese low-depressive
- Blank

Figure 4. Differentially abundant molecular clusters and microbe-metabolite co-occurrences in obesity-inflammation-depressive and inflammation status. (A) Sample plot showing log-ratio of differential molecular features relative to cluster 1 (see left panel). The corresponding right panels represent a scatterplot of samples showing log-ratio of differential features versus inflammation status. Individual samples are colored by health status. Statistical significance of the log-ratios was evaluated by pairwise comparisons using Wilcoxon rank sum test. A linear regression model was employed for regressing log-ratios against BARIC values. (B) Visualization of microbe-metabolite co-occurrences. Arrows represent microbes and dots represent metabolites. The x and y axes represent principal components of the microbe-metabolite conditional probabilities as determined by the neural network. Distances between arrow tips quantify co-occurrence strengths between microbes, while directionality of the arrows indicates which microbes and metabolites have a high probability of co-occurring. Only known microbiota-derived molecules are labeled. Microbial abundances are estimated using differential abundance analysis via multinomial regression.

A

B

795 **Table 1.** Demographic and clinical characteristics of participants.

Variable	Non-obese low depressive ^a	Obese low depressive ^b	Non-obese high depressive ^c	Obese high depressive ^d
Age	39±12.2	38.9±17.2	42.7±10.5	43.5±10.9
Sex (%female)	44	50	61.1	73.3
Race(%C/AA/Asn/NS)	72/16/12/0	37.5/37.5/12.5/12.5	55.6/16.7/27.8/0	46.7/40/13.3/0
BARIC	32.1±10.2 ^d	21.9±6.2 ^c	31.8±9 ^{cd}	25.3±7.5 ^{ac}
BMI (kg/m2)	25.1±2.9 ^{bd}	35.5±4.7 ^{ac}	26.6±2.9 ^{bd}	36±4.7 ^{ac}
BDI-T	0.5±0.8 ^{cd}	0.6±0.7 ^{cd}	7.9±5.4 ^{ab}	7.9±5 ^{ab}

796 Values presented as mean ± SD. Significant differences between groups were evaluated by
797 Mann-Whitney test and presented as superscripts. Abbreviations: C = Caucasian; AA = African-
798 American; Asn = Asian; NS = Mixed or not specified; BARIC = monocyte beta-adrenergic
799 receptor-mediated inflammation control; BMI = body mass index; BDI-T = Beck Depression
800 Inventory (BDI-Ia) total score.

Table 2. Beta-diversity analysis of 16S derived ASVs across groups.

Variable	Unweighted-UniFrac R ²	Unweighted-UniFrac F
Age	0.01	3.88***
Sex	0.01	2.54***
Race	0.03	2.92***
Time of day	0.01	0.98
BARIC	0.02	4.71***
Obesity	0.008	0.004**
Depressive symptomatology	0.01	0.001***
Obesity-depressive symptomatology co-occurrences	0.03	2.48***

Asteriks indicate statistical significance of PERMANOVA test, p<0.05.

801 **Table 3.** Post-hoc pairwise comparisons of beta-diversity between groups.

Pairwise contrasts	Unweighted- UniFrac R ²	Unweighted- UniFrac F
Obese high-depressive x Non-obese low-depressive	0.02	2.57***
Obese low-depressive x Non-obese low-depressive	0.02	1.91**
Non-obese high-depressive x Non-obese low-depressive	0.04	2.4**
Obese low-depressive x Non-obese high-depressive	0.02	2.05**
Obese low-depressive x Obese high-depressive	0.01	2.19***
Obese high-depressive x Non-obese high-depressive	0.02	2.2***

802 Asteriks indicate statistical significance of PERMANOVA test, $p < 0.05$.

Supplementary Materials and Methods

Blood collection and cellular inflammation assay

Blood samples were obtained for all participants after 12h of fasting except for plain water and collected in heparin anti-coagulant vacutainers (BD, Franklin Lakes, NJ). Cellular inflammation regulation assays were performed on heparinized whole blood within 1h of collection. Briefly, 200 pg/mL of lipopolysaccharide (LPS) (E.coli 0111:B4, catalog #L4391, Sigma-Aldrich, St. Louis, MO) was added to 300 μ L of blood in sterile 96-well polypropylene cell culture plates and incubated for 30 min at 37°C with 5% CO₂. Media-treated samples served as controls. This exogenous LPS dose was previously determined to elicit significant activation of monocytes, with 30-90% producing TNF- α [1]. Monocyte beta-adrenergic receptor-mediated inflammation control (i.e., “BARIC”) was determined based on the inhibitory effect of isoproterenol (Iso), a non-specific β 1/2AR agonist, on monocytic intracellular TNF- α production in LPS-stimulated blood as aforementioned. Briefly, LPS-stimulated blood was incubated with isoproterenol in 10⁻⁸ M final concentration and evaluated for intracellular monocyte TNF- α production using flow cytometry, as previously described [1]. The proportion of CD14^{+/dim}HLA-DR⁺ (CD14: cat. #301808; HLA-DR: cat. #307606, BioLegend, San Diego, CA) cells that were TNF- α ⁺ was determined using FlowJo software (v10, TreeStar, Ashland, OR), and gates adjusted for TNF- α -stained sample via fluorescence-minus-one controls [2,3]. Ultimately, BARIC was calculated as the arithmetic difference in %TNF- α ⁺ monocytes between LPS-treated and LPS+isoproterenol-treated samples. Greater BARIC values indicate greater β -AR responsivity, and thus, better Iso/ β -AR-mediated inflammation regulation. Smaller BARIC values may indicate impairment in

cellular pathways that regulate inflammatory responses mediated by β -ARs (e.g., diminished receptor sensitivity to agonists). BARIC measures monocytes responsivity to a β -AR agonist during an inflammatory response to LPS. Reduced BARIC has been associated with hypertension, cardiovascular disease risk factors, obesity, and higher serum cytokine levels [2,3].

Saliva collection, DNA extraction and 16S sequencing

Saliva collection procedure and 16S sequencing data was published previously [2]. However, obesity-depressive symptom relationships were not previously investigated, and instead had focused on temporal variation of the oral microbiota. Briefly, participants were provided with Salivette (Sarstedt, #51.1534, Nümbrecht, Germany) to roll the cotton Salivette inside the mouth to stimulate salivation without chewing. Saturated Salivette was placed back into the tube by mouth. Salivettes from each participant were collected at five time points across a single day: waking, mid-morning (10:00 hrs), midday (12:00 hrs), afternoon (14:00 hrs), and evening (17:00 hr). All waking samples were collected prior to oral hygiene activity, and ingestion of food or drink. In addition, participants were instructed to abstain from consuming food or drinks other than plain water for 30 min and to rinse their mouth with water prior to collection at all other time points. Next, saliva was recovered from Salivette tubes by centrifuging at 1,000 x g for 2 minutes at 4°C and stored at -80°C. DNA from saliva samples was extracted by employing Qiagen PowerSoil DNA kit as previously described [4]. V4 region of the 16S gene was amplified according to the Earth Microbiome Project protocol [5,6] and sequenced on the Illumina MiSeq sequencing platform with a MiSeq Reagent Kit v2 and paired-end 150 bp cycles.

43 **16S sequencing data processing**

44 Sequences were demultiplexed based on the barcode associated with each sample and sequence
45 quality control and ASV (Amplicon Sequence Variants) feature table construction was
46 conducted using the Deblur algorithm in QIIME2 (v.2018.4) [7]. Next, 223 potential sequencing
47 contaminants that appeared in both true and blank samples were removed from the ASV table
48 using *decontam* in R [8]. Low abundance features with fewer than 10 reads across samples and
49 singleton features present only in one sample were excluded. Taxonomy assignment was
50 performed by employing QIIME2 feature-classifier plugin with a pre-fit classifier [9] for the
51 99% reference tree of Greengenes 13_8 database. The output feature table contained an average
52 of $19,412 \pm 9,187$ sequences per sample after removal of mitochondrial and chloroplast-derived
53 sequences. Multiple rarefactions were computed to a minimum depth of 1,122 reads to mitigate
54 uneven sequencing depth across samples. This resulted in 257 samples with 1,516 unique
55 features/ASVs and 455 unique taxa. Next, alpha-diversity indices Shannon diversity index and
56 Faith's Phylogenetic Diversity were calculated. Beta-diversity, was calculated using unweighted
57 UniFrac distance, which reflects presence-absence of taxa. We performed ordination on output
58 distance matrices using principal coordinates analysis (PCoA) and following visualization using
59 EMPeror plugin in QIIME2 [10].

60 **Small molecule metabolites detection through mass spectrometry**

61 Saliva was dried and resuspended in 80% MeOH–20% water (Optima LC-MS grade; Fisher
62 Scientific, Fair Lawn, NJ, USA). Untargeted metabolomics was conducted with an ultrahigh-
63 performance liquid chromatography (Vanquish; Thermo Fisher Scientific, Waltham, MA, USA)

64 system coupled to an orbitrap mass spectrometer (QExactive, Thermo Fisher Scientific). A C18
65 reversed-phase UHPLC column (Kinetex, 1.7- μ m particles size, 50 x 2.1 mm) (Phenomenex,
66 Torrance, CA, USA) was used for chromatographic separation. A linear gradient was applied as
67 follows: 0 to 0.5 min, isocratic at 5% mobile phase (MP) B; 0.5 to 8.5 min, 100% MP B; 8.5 to
68 11 min, isocratic at 100% MP B; 11 to 11.5 min, 5% MP B; 11.5 to 12 min, 5% MP B, where
69 mobile phase A is water with 0.1% formic acid (vol/vol) and mobile phase B is
70 acetonitrile–0.1% formic acid (vol/vol) (LC-MS grade solvents; Fisher Chemical). Electrospray
71 ionization in the positive mode was used. MS spectra were acquired in the mass range of m/z 100
72 to 2,000.

73 **MS1 feature finding and data processing**

74 Raw QExactive files were converted to .mzXML format using ProteoWizard tool MSConvert
75 [11] software. Data quality was assessed by evaluating the m/z error and retention time of the
76 LC-MS standard solution (i.e., mixture of six compounds). MS1 feature finding was performed
77 in MZmine2 preprocessing workflow (MZmine-2.37.corr17.7_kai_merge2 version) available at
78 (<https://github.com/robinschmid/mzmine2/releases>) [12]. The mzMINE parameters used for
79 feature finding are as follows: mass detection (centroid; MS1, 1.5E3; MS2, 90); ADAP
80 Chromatogram builder (minimum group size in number of scans, 4; group intensity threshold,
81 5E3; minimum highest intensity, 2E3; m/z tolerance, 0.001 m/z to 20 ppm); chromatogram
82 deconvolution (local minimum search, chromatographic threshold of 96%, search minimum in
83 retention time [RT] range [minutes] of 0.03, minimum relative height of 5%, minimum absolute
84 height of 2E3, minimum ratio of peak top/edge of 1 and peak duration range [minutes] of 0 to

85 2;m/z center calculation set to auto; m/z range for MS2 scan pairing (daltons) of 0.02 and RT
86 range for MS2 scan pairing (minutes) of 0.15); isotope peaks grouper (m/z tolerance set to
87 0.0015 m/z or 10 ppm; retention time tolerance of 0.05, maximum charge of 3; and
88 representative isotope set to most intense); order peak lists; join aligner (m/z tolerance set at
89 0.0015 m/z or 15 ppm; weight for m/z of 2; retention time tolerance of 0.2 min; weight for RT of
90 1. A filter was used such that only features present in at least two samples were included.

91 **Feature based mass spectral molecular networking (FBMN)**

92 The output of aforementioned workflow, a data matrix of MS1 features that triggered MS2 scans
93 by sample (.mgf and .csv quant table), were uploaded along with the metadata file to Global
94 Natural Product Social Molecular Networking (GNPS) (<https://gnps.ucsd.edu>) [13,14]. Feature-
95 based molecular networking (version release_20) [15] was performed, and library IDs were
96 generated. Molecular networking parameters were set as follows: precursor ion mass tolerance
97 and fragment ion tolerance of 0.02 Da to cluster consensus spectra; the minimum score between
98 a pair of MS2 consensus spectra was set at 0.7 and 6 as the minimum number of ions matched as
99 described at [https://gnps.ucsd.edu/ProteoSAFe/status.jsp?](https://gnps.ucsd.edu/ProteoSAFe/status.jsp?task=f192a0030f694224a0ba8f08223a1323)
100 [task=f192a0030f694224a0ba8f08223a1323](https://gnps.ucsd.edu/ProteoSAFe/status.jsp?task=f192a0030f694224a0ba8f08223a1323). The molecular network output from GNPS was then
101 uploaded to Cytoscape (version 3.5.1 <http://www.cytoscape.org/>) [16], for advanced
102 visualization. Nodes were labelled with spectral matches to GNPS with m/z values, and edge
103 thickness is proportional to the cosine score.

104 Supplementary figures

105 **Figure S1.** Matrix of plots illustrating Pearson correlations among obesity, depressive
 106 symptoms, inflammation and sex, across participants. Histograms of the variables displayed
 107 along the matrix diagonal represent distribution of samples and scatter plots of variable pairs are
 108 displayed in the off diagonal. Correlation coefficients displayed represent the slopes of the least-
 109 squares reference lines in the scatter plots.

110 **Figure S2.** Per sample based RF analysis. (A), Receiver operating characteristic curves
111 (AUROC) illustrating classification accuracy of the random forest model across all groups (i.e.
112 controls, Ob/lower Dep, Non-ob/higher-Dep, Ob/higher-Dep) and (B), Area under precision
113 recall curves (AUPRC) illustrating performance of the random forest model across all groups.

114 **Figure S3.** Chemical diversity captured in salivary metabolomes. Branches in the circular
 115 chemical tree are colored according to the class type and branch labels represent putatively
 116 annotated chemical features at subclass level based on chemical taxonomy. Bar graphs at the leaf
 117 tips illustrate relative abundance of molecules across groups.

Relative Abundance

References

1. Hong S, Dimitrov S, Cheng T, Redwine L, Pruitt C, Mills PJ, et al. Beta-adrenergic receptor mediated inflammation control by monocytes is associated with blood pressure and risk factors for cardiovascular disease. *Brain Behav Immun*. Academic Press Inc.; 2015;50:31–8.
2. Kohn JN, Cabrera Y, Dimitrov S, Guay-Ross N, Pruitt C, Shaikh FD, et al. Sex-specific roles of cellular inflammation and cardiometabolism in obesity-associated depressive symptomatology. *Int J Obes*. Nature Publishing Group; 2019;43:2045–56.
3. Dimitrov S, Hulteng E, Hong S. Inflammation and exercise: Inhibition of monocytic intracellular TNF production by acute exercise via β 2-adrenergic activation. *Brain Behav Immun*. Academic Press Inc.; 2017;61:60–8.
4. Marotz C, Amir A, Humphrey G, Gaffney J, Gogul G, Knight R. DNA extraction for streamlined metagenomics of diverse environmental samples. *Biotechniques*. Eaton Publishing Company; 2017;62:290–3.
5. Thompson LR, Sanders JG, McDonald D, Amir A, Ladau J, Locey KJ, et al. A communal catalogue reveals Earth’s multiscale microbial diversity. *Nature*. Nature Publishing Group; 2017;551:457–63.
6. Walters W, Hyde ER, Berg-Lyons D, Ackermann G, Humphrey G, Parada A, et al. Improved Bacterial 16S rRNA Gene (V4 and V4-5) and Fungal Internal Transcribed Spacer Marker Gene Primers for Microbial Community Surveys. *mSystems*. American Society for Microbiology; 2016;1:9–15.
7. Bolyen E, Rideout JR, Dillon MR, Bokulich NA, Abnet CC, Al-Ghalith GA, et al. Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2. *Nat. Biotechnol*. Nature Publishing Group; 2019. p. 852–7.
8. Davis NM, Proctor DiM, Holmes SP, Relman DA, Callahan BJ. Simple statistical identification and removal of contaminant sequences in marker-gene and metagenomics data. *Microbiome*. BioMed Central Ltd.; 2018;6.
9. Bokulich NA, Kaehler BD, Rideout JR, Dillon M, Bolyen E, Knight R, et al. Optimizing taxonomic classification of marker-gene amplicon sequences with QIIME 2’s q2-feature-classifier plugin. *Microbiome*. BioMed Central Ltd.; 2018;6.
10. Vázquez-Baeza Y, Pirrung M, Gonzalez A, Knight R. EMPeror: A tool for visualizing high-throughput microbial community data. *Gigascience*. BioMed Central Ltd.; 2013;2.
11. Chambers MC, MacLean B, Burke R, Amodei D, Ruderman DL, Neumann S, et al. A cross-

151 platform toolkit for mass spectrometry and proteomics. *Nat. Biotechnol.* Nat Biotechnol; 2012.
 152 p. 918–20.

153 12. Pluskal T, Castillo S, Villar-Briones A, Orešič M. MZmine 2: Modular framework for
 154 processing, visualizing, and analyzing mass spectrometry-based molecular profile data. *BMC*
 155 *Bioinformatics.* BMC Bioinformatics; 2010;11.

156 13. Aron AT, Gentry EC, McPhail KL, Nothias LF, Nothias-Esposito M, Bouslimani A, et al.
 157 Reproducible molecular networking of untargeted mass spectrometry data using GNPS. *Nat*
 158 *Protoc. Nature Research;* 2020;15:1954–91.

159 14. Wang M, Carver JJ, Phelan V V., Sanchez LM, Garg N, Peng Y, et al. Sharing and
 160 community curation of mass spectrometry data with Global Natural Products Social Molecular
 161 Networking. *Nat. Biotechnol.* Nature Publishing Group; 2016. p. 828–37.

162 15. Nothias LF, Petras D, Schmid R, Dührkop K, Rainer J, Sarvepalli A, et al. Feature-based
 163 molecular networking in the GNPS analysis environment. *Nat Methods.* Nature Research;
 164 2020;17:905–8.

165 16. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: A
 166 software Environment for integrated models of biomolecular interaction networks. *Genome Res.*
 167 *Genome Res;* 2003;13:2498–504.
 168

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [Supplementarytables.xlsx](#)